This consultation closed on 25 November 2025
The APVMA is considering an application for approval of the new active constituent capromorelin tartrate, and registration of the product Eluracat Flavoured Oral Solution for Cats, containing 20 mg/mL capromorelin tartrate. The product is used for body weight gain in cats experiencing poor appetite or unintended weight loss resulting from chronic medical conditions including kidney disease.
We invite comments from 28 October to 25 November 2025 on whether approval of the active constituent and registration of the product should be granted.
The APVMA is able to consider comments relating to the legislative grounds, including:
- chemistry and manufacture
- occupational health and safety
- public health
- environmental safety
- efficacy and target animal safety.
For more information see page 19, in the APVMA Gazette No 22, Tuesday 28 October 2025.
Please send your written submission by email or post to:
Case Management
Australian Pesticides and Veterinary Medicines Authority
GPO Box 574
Canberra ACT 2601, Australia
Email: casemanagement@apvma.gov.au